# US 2021/0277015 A1 · Oga inhibitor compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277015 A1
- Document ID: US20210277015A1
- Status: Published application
- Kind: A1
- Application number: 17/253,414
- Filed: 2019-06-20
- Published: 2021-09-09
- Earliest claimed: 2018-06-20
- Applicants: Janssen Pharmaceutica NV
- Inventors: José Manuel Bartolomé-Nebreda; Andrés Avelino Trabanco-Suárez; Carlos Manuel Martinez-Viturro; Francisca Delgado-Jiménez; Susana Conde-Ceide; Juan Antonio Vega Ramiro
- Web page: https://patentgrep.com/patent/US20210277015A1

## CPC

- C07D 491/052: the oxygen-containing ring being six-membered
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 405/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 491/048: the oxygen-containing ring being five-membered
- C07D 491/056: with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C07D 498/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.

## Claims

### Claim 1

A compound of Formula (I)
or a tautomer or a stereoisomeric form thereof, wherein
RA is a heteroaryl radical selected from the group consisting of pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyridazin-3-yl, pyrimidin-4-yl, pyrimidin-5-yl, and pyrazin-2-yl, each of which may be optionally substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo; cyano; C1-4alkyl optionally substituted with 1, 2, or 3 independently selected halo substituents;
—C(O)NRaRaa; NRaRaa; and C1-4alkyloxy optionally substituted with 1, 2, or 3 independently selected halo substituents; wherein Ra and Raa are each independently selected from the group consisting of hydrogen and C1-4alkyl optionally substituted with 1, 2, or 3 independently selected halo substituents;
LA is selected from the group consisting of a covalent bond, —CH2—, —O—, —OCH2—, —CH2O—, —NH—, —N(CH3)—, —NHCH2— and —CH2NH—;
x represents 0;
R is H or CH3; and
RB is a bicyclic radical of formula (b-1), (b-2) or (b-3)
wherein
R1 and R2 are each selected from the group consisting of hydrogen, fluoro and methyl;
X1, X2 and X3 each represent CH, CF or N;
—Y1—Y2— forms a bivalent radical selected from the group consisting of
—O(CH2)mO—
(c-1);
—O(CH2)n—
(c-2);
—(CH2)nO—
(c-3);
—O(CH2)pNR3—
(c-4);
—NR3(CH2)pO—
(c-5);
—O(CH2)(CO)NR3—
(c-6);
—NR3(CO)(CH2)O—
(c-7);
—(CH2)nNR3(CO)—
(c-8);
—(CO)NR3(CH2)n—
(c-9); and
—N═CH(CO)NR3—
(c-10);
wherein
m is 1 or 2;
n and p each independently represent 2 or 3;
each R3 is independently H or C1-4alkyl;
RC is selected from the group consisting of fluoro, methyl, hydroxy, methoxy, trifluoromethyl, and difluoromethyl;
RD is selected from the group consisting of hydrogen, fluoro, methyl, hydroxy, methoxy, trifluoromethyl, and difluoromethyl; and
y represents 0, 1 or 2;
with the provisos that
a) RC is not hydroxy or methoxy when present at the carbon atom adjacent to the nitrogen atom of the piperidinediyl or pyrrolidinediyl ring;
b) RC or RD cannot be selected simultaneously from hydroxy or methoxy when RC is present at the carbon atom adjacent to C—RD;
c) RD is not hydroxy or methoxy when LA is —O—, —OCH2—, —CH2O—, —NH—, —N(CH3)—, —NH(CH2)— or —(CH2)NH—;
or a pharmaceutically acceptable addition salt or a solvate thereof.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein
RA is a heteroaryl radical selected from the group consisting of pyridin-4-yl, pyrimidin-4-yl, and pyrazin-2-yl, each of which may be optionally substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo;
C1-4alkyl optionally substituted with 1, 2, or 3 independently selected halo substituents; and
C1-4alkyloxy optionally substituted with 1, 2, or 3 independently selected halo substituents.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein LA is selected from the group consisting of a covalent bond, —CH2—, —O—, —OCH2—, —CH2O—, and —NHCH2—.

### Claim 4 (depends on 1)

The compound of claim 1, wherein RB is a bicyclic radical of formula (b-1) or (b-2).

### Claim 5 (depends on 1)

The compound of claim 1, wherein RB is a bicyclic radical of formula (b-1) or (b-2), wherein R1 is selected from the group consisting of hydrogen, fluoro and methyl; R2 is hydrogen; X1 is N or CH; and X2 is CH.

### Claim 6 (depends on 1)

The compound claim 1, wherein RB is a bicyclic radical of formula (b-1) or (b-2), wherein R1 is selected from the group consisting of hydrogen, fluoro and methyl; R2 is hydrogen; X1 is N or CH; X2 is CH; and —Y1—Y2— forms a bivalent radical selected from the group consisting of (c-1), (c-2), (c-4), (c-6) and (c-9), wherein m is 2; n is 2 or 3; and p is 2.

### Claim 7 (depends on 1)

The compound of claim 1, wherein RB is selected from the group consisting of

### Claim 8 (depends on 1)

The compound of claim 1, wherein RD is selected from the group consisting of hydrogen, fluoro, and methyl; and y represents 0 or 1.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising a prophylactically or a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13 (depends on 1)

A method of preventing or treating a disorder selected from the group consisting of tauopathy, in particular a tauopathy selected from the group consisting of Alzheimer's disease, progressive supranuclear palsy, Down's syndrome, frontotemporal lobe dementia, frontotemporal dementia with Parkinsonism-17, Pick's disease, corticobasal degeneration, and agryophilic grain disease; or a neurodegenerative disease accompanied by a tau pathology, in particular a neurodegenerative disease selected from amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations, comprising administering to a subject in need thereof, a prophylactically or a therapeutically effective amount of a compound of claim 1.

### Claim 14

(canceled)
